Introduction {#sec1}
============

The incidence and mortality of cancer is increasing worldwide \[[@B1]\]. It was estimated that approximately 18.1 million new cancer patients were diagnosed and more than half of them died worldwide during 2018 \[[@B1]\]. The etiology of cancer is complicated. Previous epidemiological studies have indicated that consumption of red meat, fried and salted meat, tobacco smoking and alcohol abuse, diabetes mellitus, obesity, non-alcoholic fatty liver disease, oxidative stress, chronic infection and inflammation can contribute to the development of cancer \[[@B4]\]. However, these potential risk factors could not fully explain the etiology of cancer. It is reported that the hereditary factor may influence the susceptibility of cancer \[[@B7],[@B8]\].

Apurinic/apyrimidinic endonuclease 1 (APE1) is a multifunctional protein which plays an important role in the pathway of base excision repair (BER). APE1 plays a pivotal role in tumor cells involving DNA damage response and regulating transcription factor activation \[[@B9]\]. The observed roles of APE1 protein allude to its potential effect on inflammation, growth, migration and angiogenesis \[[@B9]\]. In addition, APE1 may be also implicated in regulating cell cycle, oxidative stress and apoptosis \[[@B12]\]. Recently, some investigations reported that the expression level of APE1 was up-regulated in a number of cancers \[[@B13]\]. In addition, glioma cell with higher APE1 expression level was also associated with shorter time to tumor progression after chemo/radiotherapy \[[@B18],[@B19]\]. As well, previous studies reported that the decreased APE1 activity might retard cell growth of ovarian cancer \[[@B20]\] and pancreatic cancer \[[@B21]\].

*APE1* gene is approximately 3 kb in length and is located on chromosome 14q11.2 \[[@B22]\]. A number of variants in *APE1* gene are established (<https://www.ncbi.nlm.nih.gov/snp/?term=APE1>). *APE1* rs1760944 (−656T\>G) is a promoter locus and has been widely explored. Some functional studies indicated that the *APE1* rs1760944 T\>G single-nucleotide polymorphism (SNP) might decrease APE1 mRNA and protein expression levels \[[@B23],[@B24]\]. Many case--control studies were conducted to identify the potential association of *APE1* rs1760944 T\>G polymorphism with the development of cancer. Individuals with *APE1* rs1760944 GG variant might reduce 46% glioblastoma risk than those who carried *APE1* rs1760944 TT variant \[[@B25]\]. The relationship between *APE1* rs1760944 T\>G polymorphism and a decreased susceptibility of lung cancer was also found by Lu et al. \[[@B24]\]. A previous study reported that gastric cancer cases carried *APE1* rs1760944 GT/GG variants might have a better survival than others with *APE1* rs1760944 TT genotype \[[@B26]\]. But the results were conflicting. Two meta-analyses suggested that this SNP was correlated with a decreased susceptibility of cancer in Asian populations and lung cancer \[[@B27],[@B28]\]. Recently, many investigations focused on the association between *APE1* rs1760944 T\>G polymorphism and the risk of other cancers. The findings were more confusing. The aim of the present study was to carry out a meta-analysis to evaluate whether this SNP was associated with the risk of cancer.

Materials and methods {#sec2}
=====================

Literature search parameters {#sec2-1}
----------------------------

PubMed and Embase databases were exhaustively searched for relevant publications which studied the relationship of *APE1* rs1760944 T\>G locus with the risk of cancer from the inception up to 17 March 2019. The search strategy was: (polymorphism OR SNP) and (apurinic/apyrimidinic endonuclease 1 or APE1 or APE-1) and (cancer OR carcinoma). In the current study, publications written in English or Chinese were eligible. Moreover, the references of the included studies, comments, meta-analyses and reviews were manually retrospected to recruit the potential literatures.

Inclusion criterion {#sec2-2}
-------------------

For eligibility, publications were required to meet the following inclusion criteria: (1) case--control studies investigating the relationship between the *APE1* rs1760944 T\>G locus and the risk of cancer; (2) the diagnosis of cases was confirmed by pathological examination; (3) the frequencies of alleles or genotypes were presented; (4) the paper was written in English or Chinese.

Exclusion criteria {#sec2-3}
------------------

Studies were excluded based on the major exclusion criteria: (1) not case--control design; (2) studies did not provide genotyping data on *APE1* rs1760944 T\>G polymorphism; and (3) meta-analyses/reviews, comments and letters focusing on the relationships between the *APE1* rs1760944 T\>G locus and cancer risk.

Data extraction {#sec2-4}
---------------

Two authors (Guowen Ding and Yu Chen) reviewed each eligible study independently. They extracted the following terms from case--control studies, including the first author name, publishing year, country where the study was carried out, ethnicity, the source of control, cancer type, numbers of included cases and controls in each case--control study, genotyping data, the method of polymerase chain reaction, statistical method and evidence of Hardy--Weinberg equilibrium (HWE) evaluation in control group. If the extracted data had any dispute, authors settled these issues following a detailed discussion among all reviewers.

Statistical analysis {#sec2-5}
--------------------

HWE in controls was assessed by an online Pearson's χ^2^ test (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). We calculated crude odds ratios (ORs) and 95% confidence intervals (CIs) to evaluate the correlation of *APE1* rs1760944 T\>G polymorphism and cancer risk. The following four genetic models were used, including homozygote model (GG vs. TT), dominant model (GG/TG vs. TT), recessive model (GG vs. TT/TG) and allele model (G vs. T). Cochran's Q-statistic and *I^2^* test were used to check the heterogeneity among the included studies. The random-effect model was harnessed when *I^2^* \> 50% or *P*\<0.10 \[[@B29]\]; otherwise, a fixed-effect model was used \[[@B30]\]. Subgroup analyses were performed to explore the heterogeneity source among the studies. Ethnicity, the source of control and cancer type was considered as the potential source of heterogeneity. Begg's funnel plots and Egger's linear regression test were used to detect the potential bias in this meta-analysis. Since significant bias was identified in the present study, non-parametric 'trim-and-fill' method was used to evaluate the stability of the observed results. Sensitivity analysis was conducted by one-way method, which deleted each study one by one and re-calculated the pooled ORs and CIs. All statistical analyses were conducted by using STATA 12.0 (Stata Corporation, TX, U.S.A.). A *P*-value (two-sided) \<0.05 was defined as statistically significant.

Results {#sec3}
=======

Characteristics of eligible case--control studies {#sec3-1}
-------------------------------------------------

[Figure 1](#F1){ref-type="fig"} shows the selection process of the eligible publications. A total of 343 papers were collected. According to the major inclusion criteria, there were 20 papers (including 23 independent case--control studies) focusing on the relationship of *APE1* rs1760944 T\>G polymorphism with cancer risk \[[@B23],[@B31]\]. Among them, five investigated lung cancer \[[@B24],[@B31]\], three investigated colorectal cancer \[[@B34]\], three investigated breast cancer \[[@B37]\], three investigated cervical cancer \[[@B40],[@B41]\], two investigated osteosarcoma \[[@B23]\], two investigated nasopharyngeal carcinoma \[[@B42],[@B43]\] and five investigated other cancers (bladder cancer \[[@B44]\], glioblastoma \[[@B25]\], renal cell carcinoma \[[@B45]\], prostate cancer \[[@B46]\] and ovarian cancer \[[@B47]\]). Additionally, twenty-one had Asian and two had Caucasian ethnicities. In all included studies, χ^2^ test was used to calculate the pooled ORs and CIs. The detailed characteristics of the included case--control studies are shown in [Table 1](#T1){ref-type="table"}. The number of each genotype and HWE are presented in [Table 2](#T2){ref-type="table"}.

![Flow diagram of included and excluded processes](bsr-39-bsr20190866-g1){#F1}

###### Characteristics of all included studies in the meta-analysis

  Author              Year   Country   Ethnicity    The type of cancer            Genotyping method               Source of control   Sample size (case/control)   Statistical methods
  ------------------- ------ --------- ------------ ----------------------------- ------------------------------- ------------------- ---------------------------- ------------------------------------------
  Berndt et al.       2007   U.S.A.    Caucasians   Advanced colorectal adenoma   Taqman                          PB                  767/720                      χ^2^ test
  Lu et al.           2009   China     Asians       Lung cancer                   Illumina                        PB                  500/517                      χ^2^ test, SPSS 15.0
  Lo et al.           2009   China     Asians       Lung cancer                   MassARRAY                       HB                  730/730                      χ^2^ test, SAS
  Lu et al.           2009   China     Asians       Lung cancer                   Illumina                        HB                  572/547                      χ^2^ test, SPSS 15.0
  Wang et al.         2010   China     Asians       Bladder cancer                PCR-RFLP                        HB                  234/253                      χ^2^ test, SAS
  Zhou et al.         2011   China     Asians       Glioblastoma                  MALDI-TOF                       HB                  766/824                      χ^2^ test, SPSS 15.0
  Li et al.           2011   China     Asians       Lung cancer                   PCR-CTPP                        HB                  455/443                      χ^2^ test, SPSS 16.0
  Cao et al.          2011   China     Asians       Renal cell carcinoma          TaqMan                          HB                  612/632                      χ^2^ test, *t* test, SAS
  Wang et al.         2013   China     Asians       Cervical cancer               PCR-RFLP                        HB                  306/306                      χ^2^ test, *t* test, SAS
  Jing et al.         2013   China     Asians       Prostate cancer               PCR-RFLP                        HB                  198/156                      χ^2^ test, SPSS 16.0
  Kang et al.         2013   China     Asians       Breast cancer                 TaqMan                          HB                  500/799                      χ^2^ test, SAS
  Pan et al.          2013   China     Asians       Lung cancer                   PCR-LDR                         HB                  819/803                      χ^2^ test, Open-source R software
  Zhang et al.        2013   China     Asians       Ovarian cancer                DNA sequence                    HB                  124/141                      χ^2^ test, SPSS 16.0
  Li et al.           2013   China     Asians       Nasopharyngeal carcinoma      PCR-CTPP                        HB                  231/300                      χ^2^ test, SPSS 16.0
  Zhang et al.        2014   China     Asians       Colorectal cancer             PCR-CTPP                        HB                  247/300                      χ^2^ test, SPSS 19.0
  Luo et al.          2014   China     Asians       Breast cancer                 PCR-CTPP                        HB                  194/245                      χ^2^ test, SPSS 16.0
  Mashayekhi et al.   2015   Iran      Caucasians   Breast cancer                 T-ARMS-PCR                      HB                  150/150                      χ^2^ test, Medcalc software 12.1
  Lai et al.          2016   China     Asians       Colorectal cancer             High resolution melting assay   HB                  727/736                      χ^2^ test, SAS9.2
  Meng et al.         2017   China     Asians       Cervical cancer               TaqMan                          HB                  571/657                      χ^2^ test
  Meng et al.         2017   China     Asians       Cervical cancer               TaqMan                          HB                  608/1165                     χ^2^ test
  Xiao et al.         2017   China     Asians       Osteosarcoma                  TaqMan                          HB                  172/256                      χ^2^ test, SPSS 22.0, GraphPad Prism 6.0
  Xiao et al.         2017   China     Asians       Osteosarcoma                  TaqMan                          HB                  206/360                      χ^2^ test, SPSS 22.0, GraphPad Prism 6.0
  Lu et al.           2017   China     Asians       Nasopharyngeal carcinoma      MassARRAY                       HB                  477/558                      χ^2^ test, SPSS 17.0

Abbreviations: MALDI-TOF MS, matrix-assisted laser desorption/ionization time of flight mass spectrometry; PCR-CTPP, polymerase chain reaction with confronting two-pair primers; PCR-LDR, polymerase chain reaction-ligase detection reaction; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; T-ARMS-PCR, tetra-primer amplification refractory mutation system-polymerase chain reaction.

###### Distribution of *APE1* rs1760944 T\>G polymorphism genotype and allele among cases and controls

  Author              Year   case   control       case   control   HWE                                            
  ------------------- ------ ------ ------------- ------ --------- ------------- ----- ------ ----- ------ ------ -----
  Berndt et al.       2007   106    310           244    114       317           243   798    522   803    545    Yes
  Lu et al.           2009   184    241           75     170       238           109   391    609   456    578    Yes
  Lo et al.           2009   271    332           122    234       341           153   576    874   647    809    Yes
  Lu et al.           2009   199    288           85     149       293           105   458    686   503    591    Yes
  Wang et al.         2010   92     108           34     77        124           52    176    292   228    278    Yes
  Zhou et al.         2011   233    392           125    237       424           155   642    858   734    898    Yes
  Li et al.           2011   162    227           66     143       206           94    359    551   394    492    Yes
  Cao et al.          2011   170    307           135    191       307           134   577    647   575    689    Yes
  Wang et al.         2013   121    139           46     92        154           60    231    381   274    338    Yes
  Jing et al.         2013   78     93            27     47        76            33    147    249   142    170    Yes
  Kang et al.         2013   180    207           78     248       381           170   363    567   721    877    Yes
  Pan et al.          2013   114    384           321    98        369           336   1026   612   1041   565    Yes
  Zhang et al.        2013   48     52            24     46        65            30    100    148   125    157    Yes
  Li et al.           2013   71     126           34     94        143           63    194    268   269    331    Yes
  Zhang et al.        2014   93     102           52     93        140           67    206    288   274    326    Yes
  Luo et al.          2014   64     86            44     70        128           47    174    214   222    268    Yes
  Mashayekhi et al.   2015   58     80            12     41        102           7     104    196   116    184    No
  Lai et al.          2016   217    368           136    211       380           140   640    802   660    802    Yes
  Meng et al.         2017   182    285           104    211       324           122   493    649   568    746    Yes
  Meng et al.         2017   199    298           111    386       564           215   520    696   994    1336   Yes
  Xiao et al.         2017   80     70            22     86        121           49    114    230   219    293    Yes
  Xiao et al.         2017   83     93            30     108       178           74    153    259   326    394    Yes
  Lu et al.           2017   189    GT/GG = 288          179       GT/GG = 379                                    Yes

Quantitative synthesis {#sec3-2}
----------------------

A total of 23 independent case--control studies with 10166 cancer cases and 11598 controls were included to explore the potential correlation of *APE1* rs1760944 T\>G polymorphism with the susceptibility of cancer \[[@B23],[@B31]\]. We found that *APE1* rs1760944 T\>G polymorphism conferred statistical evidence of the relationship between *APE1* rs1760944 T\>G locus and a decreased risk of cancer (G vs. T: OR, 0.87; 95% CI, 0.83--0.92 *P*\<0.001; GG vs. TT: OR, 0.77; 95% CI, 0.69--0.86; *P*\<0.001; GG/TG vs. TT: OR, 0.83; 95% CI, 0.77--0.89, *P*\<0.001 and GG vs. TT/TG: OR, 0.85; 95% CI, 0.80--0.92, *P*\<0.001; [Table 3](#T3){ref-type="table"}).

###### Results of the meta-analysis from different genetic models

                            Number of cases/controls   G vs. T                 GG vs. TT     GG/TG vs. TT   GG vs. TT/TG                                                                                                                                                             
  ------------------------- -------------------------- ----------------------- ------------- -------------- -------------- ----------------------- ------------- ------- ------- ----------------------- ------------- ------- ------- ----------------------- ------------- ------- -------
  Total                     9997/11537                 **0.87 (0.83--0.92)**   **\<0.001**   43.9%          0.015          **0.77 (0.69--0.86)**   **\<0.001**   39.4%   0.031   **0.83 (0.77--0.89)**   **\<0.001**   35.8%   0.046   0.85 (0.80**--**0.92)   **\<0.001**   26.8%   0.121
  HWE                                                                                                                                                                                                                                                                                
    Yes                     9847/11387                 **0.87 (0.82--0.92)**   **\<0.001**   46.4%          0.011          **0.77 (0.69--0.85)**   **\<0.001**   41.1%   0.026   **0.83 (0.77--0.90)**   **\<0.001**   35.1%   0.054   **0.85 (0.79--0.91)**   **\<0.001**   24.4%   0.151
    No                                                 0.84 (0.60**--**1.17)   0.310         \-             \-             1.21 (0.44**--**3.34)   0.710         \-      \-      **0.60 (0.37--0.97)**   **0.038**     \-      \-      1.78 (0.68**--**4.64)   0.241         \-      \-
  Ethnicity                                                                                                                                                                                                                                                                          
    Caucasians              810/824                    1.00 (0.87**--**1.15)   0.994         20.0%          0.264          1.09 (0.81**--**1.48)   0.573         0.0%    0.832   0.82 (0.47**--**1.45)   0.502         75.1%   0.045   1.07 (0.86**--**1.33)   0.539         11.5%   0.288
    Asians                  9187/10713                 **0.86 (0.82--0.91)**   **\<0.001**   42.4%          0.024          **0.75 (0.67--0.84)**   **\<0.001**   36.3%   0.054   **0.82 (0.76--0.89)**   **\<0.001**   32.9%   0.073   **0.83 (0.78--0.90)**   **\<0.001**   17.7%   0.234
  Cancer type                                                                                                                                                                                                                                                                        
    Colorectal cancer       1628/1705                  0.97 (0.88**--**1.07)   0.607         0.0%           0.396          0.96 (0.79**--**1.17)   0.682         0.0%    0.510   0.93 (0.80**--**1.09)   0.388         15.3%   0.307   1.00 (0.86**--**1.17)   0.983         0.0%    0.873
    Lung cancer             3071/3038                  **0.83 (0.78--0.90)**   **\<0.001**   0.0%           0.717          **0.68 (0.59--0.79)**   **\<0.001**   0.0%    0.702   **0.80 (0.72--0.90)**   **\<0.001**   0.0%    0.795   **0.77 (0.68--0.87)**   **\<0.001**   10.8%   0.344
    Cervical cancer         1485/2128                  0.93 (0.79**--**1.09)   0.361         61.4%          0.075          0.87 (0.65**--**1.17)   0.367         51.5%   0.127   0.90 (0.71**--**1.15)   0.416         62.3%   0.071   0.93 (0.78**--**1.11)   0.433         0.0%    0.438
    Breast cancer           809/1194                   **0.83 (0.73--0.95)**   **0.005**     4.3%           0.352          **0.75 (0.57--0.98)**   **0.034**     37.6%   0.202   **0.71 (0.59--0.86)**   **\<0.001**   0.0%    0.635   1.04 (0.65**--**1.67)   0.870         62.1%   0.072
    Nasopharyngeal cancer   708/858                    0.89 (0.70**--**1.14)   0.355         \-             \-             0.71 (0.43**--**1.20)   0.204         \-      \-      0.84 (0.59**--**1.18)   0.316         58.5%   0.120   0.65 (0.41**--**1.03)   0.064         \-      \-
    Osteosarcoma            378/616                    **0.69 (0.57--0.83)**   **\<0.001**   0.0%           0.701          **0.51 (0.35--0.75)**   **0.001**     0.0%    0.823   **0.61 (0.47--0.80)**   **\<0.001**   0.0%    0.748   **0.64 (0.45--0.91)**   **0.014**     0.0%    0.867
    Others                  1918/1998                  0.87 (0.75**--**1.02)   0.080         58.0%          0.049          0.77 (0.57**--**1.03)   0.083         54.7%   0.065   0.89 (0.78**--**1.02)   0.109         47.8%   0.105   0.87 (0.74**--**1.02)   0.079         22.3%   0.273
  Source of control                                                                                                                                                                                                                                                                  
    Population-based        1160/1191                  0.92 (0.73**--**1.17)   0.506         75.6%          0.043          0.83 (0.50**--**1.40)   0.494         78.5%   0.031   0.93 (0.77**--**1.13)   0.485         28.9%   0.236   0.84 (0.54**--**1.31)   0.448         80.5%   0.024
    Hospital-based          8837/10346                 0.87 (0.82**--**0.92)   **\<0.001**   41.3%          0.028          **0.76 (0.68--0.85)**   **\<0.001**   35.5%   0.059   0.82 (0.75**--**0.88)   **\<0.001**   36.7%   0.048   0.85 (0.79**--**0.92)   **\<0.001**   18.3%   0.226

Bold values are statistically significant (*P*\< 0.05).

When we conducted subgroup analyses according to the different populations, the findings indicated that *APE1* rs1760944 T\>G polymorphism might be a protective factor for the development of cancer in Asian population (G vs. T: OR, 0.86; 95% CI, 0.82--0.91 *P*\<0.001; GG vs. TT: OR, 0.75; 95% CI, 0.67--0.84; *P*\<0.001; GG/TG vs. TT: OR, 0.82; 95% CI, 0.76--0.89, *P*\<0.001 and GG vs. TT/TG: OR, 0.83; 95% CI, 0.78--0.90, *P*\<0.001; [Figure 2](#F2){ref-type="fig"}).

![Meta-analysis for the association of cancer risk with the *APE1* rs1760944 T\>G polymorphism (random-effect, allele comparing model)](bsr-39-bsr20190866-g2){#F2}

When we conducted subgroup analyses according to cancer type, the results suggested that *APE1* rs1760944 T\>G polymorphism decreased the risk of lung cancer (G vs. T: OR, 0.83; 95% CI, 0.78--0.90, *P*\<0.001; GG vs. TT: OR, 0.68; 95% CI, 0.59--0.79; *P*\<0.001; GG/TG vs. TT: OR, 0.80; 95% CI, 0.72--0.90, *P*\<0.001 and GG vs. TT/TG: OR, 0.77; 95% CI, 0.68--0.87, *P*\<0.001), breast cancer (G vs. T: OR, 0.83; 95% CI, 0.73--0.95, *P*=0.005; GG vs. TT: OR, 0.75; 95% CI, 0.57--0.98; *P*=0.034 and GG/TG vs. TT: OR, 0.71; 95% CI, 0.59--0.86, *P*\<0.001), and osteosarcoma (G vs. T: OR, 0.69; 95% CI, 0.57--0.83 *P*\<0.001; GG vs. TT: OR, 0.51; 95% CI, 0.35--0.75; *P*=0.001; GG/TG vs. TT: OR, 0.61; 95% CI, 0.47--0.80, *P*\<0.001 and GG vs. TT/TG: OR, 0.64; 95% CI, 0.45--0.91, *P*=0.014).

Publication bias and non-parametric 'trim-and-fill' method {#sec3-3}
----------------------------------------------------------

In the present study, Begg's and Egger's tests were used to assess the potential bias among the eligible studies. Evidence of bias was found in the present study (G vs. T: Begg's test *P*=0.055, Egger's test *P*=0.013; GG vs. TT: Begg's test *P*=0.037, Egger's test *P*=0.080; GG/TG vs. TT: Begg's test *P*=0.051, Egger's test *P*=0.016; GG vs. TT/TG: Begg's test *P*=0.055, Egger's test *P*=0.174; [Figure 3](#F3){ref-type="fig"}).

![For *APE1* rs1760944 T\>G polymorphism, Begg's funnel plot analysis for publication bias (allele comparing model)](bsr-39-bsr20190866-g3){#F3}

Since bias was found, we used non-parametric 'trim-and-fill' method to evaluate the stability of results. When we treated the publication bias, the adjusted ORs and CIs were not significantly changed ([Figure 4](#F4){ref-type="fig"}).

![For *APE1* rs1760944 T\>G polymorphism, filled funnel plot of meta-analysis (allele comparing model)](bsr-39-bsr20190866-g4){#F4}

Sensitivity analysis {#sec3-4}
--------------------

In this meta-analysis, sensitivity analysis was conducted by one-way method, which deleted an individual case--control study one by one and re-calculated the pooled ORs and CIs. No single case--control study significantly influenced the final decision ([Figure 5](#F5){ref-type="fig"}).

![Sensitivity analysis of the influence in G vs. T genetic model (random-effects estimates)](bsr-39-bsr20190866-g5){#F5}

Heterogeneity {#sec3-5}
-------------

We found significant heterogeneity in all genetic models. Considering the potential factors for heterogeneity, subgroup analysis was conducted to identify its major source. In this meta-analysis, Asians, cervical cancer and population-based studies contribute to the major sources of heterogeneity.

Discussion {#sec4}
==========

The *APE1* rs1760944 T\>G has been frequently investigated due to its potential role in the development of cancer; however, the results are conflicting. To shed light on this issue, we performed an extensive meta-analysis. The results highlighted that *APE1* rs1760944 T\>G polymorphism decreased the risk of cancer. Results of subgroup analyses demonstrated that this SNP still significantly modified the risk among lung cancer, breast cancer, osteosarcoma patients and Asians.

Rs1760944 T\>G is a promoter SNP in the *APE1* gene and may affect the binding of transcription factors. Since 2007, a number of case--control studies were performed to assess the potential relationship of *APE1* rs1760944 T\>G polymorphism with the risk of cancer, but the observations were controversial. Several investigations suggested that *APE1* rs1760944 T\>G SNP decreased the susceptibility of cancer \[[@B23],[@B24],[@B31],[@B32],[@B37],[@B38],[@B40],[@B42],[@B44],[@B46]\]. However, other case--control studies suggest null correlation between the *APE1* rs1760944 T\>G SNP and cancer risk \[[@B25],[@B33],[@B39],[@B41],[@B43],[@B45],[@B47]\]. How can we obtain an extensive evaluation of the relationship between *APE1* rs1760944 T\>G locus and the risk of cancer with the consistent conclusions? To our knowledge, small sample size investigation could lead to confusing findings. Thus, we carried out a meta-analysis with 23 independent case--control studies to explore the correlation between *APE1* rs1760944 T\>G SNP and the susceptibility of cancer. In the included case--control studies, χ^2^ test was used to calculate the pooled ORs and CIs. In meta-analysis, we also used χ^2^ test to evaluate the relationship of *APE1* rs1760944 T\>G polymorphism with cancer risk. Overall, we found that *APE1* rs1760944 T\>G polymorphism decreased the risk of cancer in four genetic models. When we conducted subgroup analyses, we found that *APE1* rs1760944 T\>G polymorphism decreased the risk of lung cancer, breast cancer, osteosarcoma and Asians. To the best of our knowledge, the association might be confounded by some potential bias (e.g. publication bias, heterogeneity and lack of accordance with HWE in controls). Thus, we subsequently performed subgroup analyses. The findings suggested that the *APE1* rs1760944 T\>G polymorphism might be a protective effect on the development of cancer in Asians only, but not Caucasians. In the present study, one case--control study was incongruent with HWE \[[@B37]\]. When we deleted it and re-calculated the pooled ORs and CIs, the significant relationship was not changed. In the present study, we conducted non-parametric 'trim-and-fill' method to explore the potential influence of publication bias. We found that the bias of publication might not alter the findings. We also found that *APE1* rs1760944 T\>G polymorphism still significantly decreased the risk of some type of cancers.

It was found that inhibition of APE1 activity might reduce cell growth of ovarian cancer \[[@B20]\] and pancreatic cancer \[[@B21]\]. In addition, Luo et al. \[[@B48]\] identified that a decreased APE1 activity could also significantly retard the proliferation of endothelial cells, suggesting its stimulative effect on the development of cancer. Several studies indicated that *APE1* rs1760944 G allele decreased *APE1* mRNA and protein expression levels \[[@B23],[@B24]\]. Additionally, Lu et al. \[[@B24]\] reported that *APE1* rs1760944 G allele was associated with a decreased level of APE1 mRNA by reducing the binding affinity of some transcription factors. Although the pathway of the relationship between *APE1* rs1760944 T\>G and cancer risk has been not confirmed, it is speculated that this SNP may alter the susceptibility of cancer through the mechanism mentioned above. All observations and speculations should be verified with new molecular studies.

Some limitations of the current analysis should be noted. First, in this meta-analysis, only published literature was eligible and included, and some presumable unpublished studies might be neglected and discarded. Second, heterogeneity and publication bias were apparent, which could distort the pooled results. Our findings should be interpreted with cautions. Third, for lack of sufficient data (e.g., smoking, drinking, age, sex and vegetable and fruit intake and other environmental factors), we only conducted a crude assessment. Finally, only *APE1* rs1760944 T\>G polymorphism was included to assess the association with the risk of cancer; other functional loci in *APE1* gene should not been ignored.

In summary, this updated meta-analysis highlights that the *APE1* rs1760944 T\>G polymorphism may play a protective role in the development of cancer. Further studies in different race are needed to confirm or refute our findings.
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